Jam

  • ANGLE PLC: 2025 AGM Results Announced

    ANGLE plc announced all resolutions were passed at its 2025 Annual General Meeting. The global leader in liquid biopsy technology, known for its Parsortix® PC1 System, focuses on circulating tumor cell (CTC) solutions for research, drug development, and clinical oncology. The company offers clinical services and diagnostic products, backed by over 100 peer-reviewed publications.

    2025年6月30日
  • Robinhood’s Crypto Expansion: Stock Tokens, Layer 2, EU/US Futures & Staking

    Robinhood is expanding its global reach with stock and ETF tokens for EU investors, marking a significant entry into the European market. The company is also developing its own Layer 2 blockchain for tokenized assets. Additionally, Robinhood is launching crypto perpetual futures in the EU and crypto staking for US customers, further broadening its crypto offerings and aiming to make investing more accessible worldwide.

    2025年6月30日
  • Ravi Kapoor Joins SOHM, Inc. Board as Independent Director

    SOHM, Inc. appointed Ravi Kapoor as an Independent Director. Kapoor brings over 30 years of experience in corporate law, M&A, and financial management. His expertise is expected to enhance SOHM’s strategic direction, corporate governance, and growth initiatives, particularly aligning with the company’s focus on generic drugs and gene-editing technologies.

    2025年6月30日
  • FOXO Behavioral Health Subsidiary Approved for Scott County Opioid Funds

    FOXO Technologies’ subsidiary, Myrtle Recovery Centers, has secured a second year of funding from Scott County for its opioid abatement program. This renewed support will allow Myrtle to continue providing essential care to uninsured patients at its Tennessee facility. The company is experiencing high demand and plans for further expansion.

    2025年6月30日
  • Qifu Technology Concludes Annual General Meeting, Reports Results

    Qifu Technology, Inc. shareholders approved a rebranding to Qfin Holdings, Inc. and restated Articles of Association. Deloitte Touche Tohmatsu was reappointed as auditor, and Mr. Xiangge Liu will continue as director. These changes reflect the Chinese AI-powered Credit-Tech platform’s commitment to strengthening governance and identity in the evolving fintech sector.

    2025年6月30日
  • Faraday X Reveals FX Super One EAI-MPV, FF Super EAI F.A.C.E. System, and Embodied Intelligence AI Agent 6×4 Architecture at FX Super One Preview

    Faraday Future introduced its FX brand and the FX Super One MPV at a private preview in Los Angeles. The event showcased groundbreaking innovations like the FF Super EAI F.A.C.E. System and FF EAI Embodied Intelligence AI Agent 6×4 Architecture. A global public launch is set for July 17 in Los Angeles, marking the start of pre-orders for this mass-market, AI-enabled electric vehicle.

    2025年6月30日
  • SEALSQ Completes Strategic Investment in WeCan Group, Acquiring 28.30% Stake

    SEALSQ Corp has acquired a 28.30% stake in WeCan Group SA, a Swiss blockchain innovator. This strategic investment aims to accelerate the development of quantum-resilient, blockchain-based security solutions for finance, IoT, and Web 3.0. The partnership will integrate post-quantum cryptography, PKI, and blockchain compliance platforms, enhancing KYC/KYB solutions, fortifying IoT devices, and expanding decentralized identity offerings.

    2025年6月29日
  • Singapore Transport Minister Visits WeRide to Boost Autonomous Mobility Cooperation

    Singapore is integrating self-driving vehicles into its public transport by late 2025, starting with residential areas. This move follows a visit by Singapore’s transport minister to WeRide, an autonomous driving leader. The partnership aims to accelerate AV deployment and improve connectivity, addressing demographic shifts and labor shortages. Singapore plans to expedite AV adoption over the next five years with WeRide’s support.

    2025年6月29日
  • Central Gawler Mill’s Stage 1 Gold Resources Grow to 223koz

    Barton Gold Holdings Limited has updated its Mineral Resources Estimate for the Challenger Gold Project, focusing on higher-grade open pit materials and tailings reprocessing. This strategic shift aims to de-risk and accelerate production, with initial “Stage 1” operations targeting late 2026. The company plans feasibility studies by year-end 2025, leveraging existing infrastructure to reduce cost and risk.

    2025年6月29日
  • Aurinia Pharmaceuticals to Host Conference Call to Discuss AUR200 Phase 1 Study Results on June 30, 2025

    Aurinia Pharmaceuticals will present Phase 1 study results for its investigational therapy AUR200 on June 30, 2025. The company, focused on autoimmune diseases, previously launched LUPKYNIS and is developing AUR200 as a dual inhibitor targeting BAFF and APRIL. The findings will be shared via webcast and conference call.

    2025年6月29日